{"entity":{"id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","aka":[],"tldr":"A phase 2 trial of DZD8586 and Venetoclax in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.","summary":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) is a phase 2 interventional study registered as NCT07154264 by Dizal Pharmaceuticals, with 66 participants planned, started 2025-09-22 and due to reach its primary completion in 2029-12. Interventions recorded: DZD8586 and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07154264","url":"https://clinicaltrials.gov/study/NCT07154264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["dzd8586","venetoclax"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07154264","phase":"2","setting":"A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)","sponsor":"Dizal Pharmaceuticals","enrolled":66,"outcomes":[]},"route":"/trials/nct07154264/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}